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Abstract
Relapsed, refractory lymphoma remains to be a challenge and lacks efficient treatment.
Some tumor cells escape from treatment, become resistant to chemotherapeutic agents,
and rapidly regenerate into large tumors. Lymphoma cells induce accumulation of Gr-1+-
CD11b+ myeloid derived suppressor cells (MDSCs) in lymphatic organs and their vicinity.
MDSCs enable tumor cells to escape from immune cells mediated surveillance and attack.
Gemcitabine is a chemotherapeutic agent that eliminates both tumor cells and MDSCs,
improving the immune environment favorable for subsequent treatment. We evaluated the
effects of low dose gemcitabine combined with intra-tumorally delivered dendritic cells
(DCs) for the treatment of A20 large-size lymphoma. We showed that MDSCs increased
markedly in lymphoma-bearing mice, and that gemcitabine significantly increased the apo-
ptosis of MDSCs. Treatment of lymphoma with either gemcitabine or intra-tumoral DCs
alone could not inhibit tumor growth or rescue lymphoma-bearing mice. Treatment of lym-
phoma with small dose gemcitabine followed by intra-tumorally injected DCs significantly
improved the efficacy of either individual treatment by reducing MDSCs, inducing onsite
DCs maturation, eliminating tumor cells, inhibiting tumor growth and relapse, and extending
the survival of the lymphoma-bearing mice, partly through the induction of the IFNγ secret-
ing cells and the activation of cytotoxic lymphocytes. We showed that NK cells and CD8+ T
cells were the major effectors to mediate the inhibition of tumor growth. Thus, the observa-
tion that gemcitabine synergizes DCs mediated immunotherapy to improve the efficacy of
large size lymphoma treatment provides an experimental basis for the combination of che-
motherapy and immunotherapy for the efficient treatment of relapsed or refractory
lymphoma.
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Introduction
Lymphomas represent the fourth most common hematologic malignancy among western
countries [1]. They are highly heterogeneous diseases, varying by both the type of malignant
cell and the tumor location. Nowadays chemotherapy is the major option for treatment of both
Hodgkin's and non-Hodgkin's lymphomas [2]. For large size lymphomas, treatment with
deliberately designed chemotherapeutic regime can efficiently inhibit tumor growth and elimi-
nate the majority of tumor cells. However, a small number of residual tumor cells that manage
to escape from chemotherapeutic treatment become resistant or unresponsive to the original
treatment. These relapsed or refractory lymphomas still remain a challenge and lack efficient
clinical treatment. Thus, novel strategies are required to develop for the treatment of relapsed
or refractory lymphomas.
Tumor cells can be recognized by tumor-specific T cells [3]. Moreover, tumor infiltration
with cytotoxic T lymphocytes (CTLs) and T helper cells represents a favorable prognostic fac-
tor for lymphoma patients. Tumor-specific T cells can be activated by vaccination with den-
dritic cells (DCs) [4,5,6]. DCs are unique antigen-presenting cells that deliver exogenous
antigens into the major histocompatibility complex (MHC) class I processing pathway to acti-
vate CTLs [7]. Contact with microbial, inflammatory, and T cell-derived activation signals
induces DC maturation and secretion of cytokine molecules, which in turn activate CTLs, nat-
ural killer (NK) cells, and interferon gamma (IFNγ)-producing T helper type 1 (Th1) cells.
Vaccination with in vitro pulsed, tumor antigen-loaded DCs has been shown to elicit anti-
tumor CTL responses and to induce tumor regression in cancer patients [8]. However, a num-
ber of recent clinical trials of vaccination with lymphoma antigen-activated DCs have failed to
demonstrate the expected, desired results [9]. One of the reasons is that tumor antigen pulsed,
in vitromatured DCs may not be as efficient as in vivomatured DCs in either function or quan-
tity. Another possible reason is that relapsed, refractory lymphomas that resistant to chemo-
therapeutic agents often form large size tumors, but Immune cancer therapy with DCs is more
efficient to eliminate small size tumors rather than tumors with large size [10,11]. Finally, it is
proposed that tumors can form an immunosuppressive environment rendering them insensi-
tive to T cells and NK cells [12,13]. Thus, the improvement of the current DC based immuno-
therapy and the combination of multiple strategies, including radiation therapy, chemotherapy
and other immunotherapy, are required to achieve more efficient treatment of the large lym-
phoma in patients.
Myeloid derived suppressor cells (MDSCs) are a population of cells derived from the mye-
loid lineages that can account for 10–40% of spleen nucleated cells of tumor-bearing animals
[14]. These cells had the ability to inhibit T cell proliferation, to promote tumor growth, and to
suppress graft-versus-host disease (GVHD) [15]. Young et al first described the accumulation
of a large number of myeloid suppressor cells around tumor tissues of patients with head and
neck cancer and renal cell carcinoma patients [16]. In mouse the characteristic immunopheno-
type of MDSCs is the expression of myeloid cell surface markers, CD11b and Gr-1 [17]. In
human MDSCs their cell surface immunophenotype is CD11b+CD15+CD33+CD13+ CD34+-
CD14-HLA-DR- [18]. Through the production of nitric oxide (NO) and L-arginine (ARG1),
MDSCs from tumor-bearing animals suppress the expression of the CD3z chain of the T-cell
receptor and L-Selectin, inhibit antigen-specific responses from CD8+ T cells, induce to gener-
ate regulatory T cells, IL-7 and IL-15, and inhibit the NK cells and the cytotoxic activity of
NKT cells [19,20,21,22,23,24,25,26]. Given these immunosuppressive effects, it has been pro-
posed that elimination of these myeloid suppressor cells may significantly improve anti-tumor
responses and enhance effects of cancer immunotherapy [17]. Kusmartsev et al. reported that
all-trans retinoic acid (ATRA) was able to induce differentiation of CD11b+Gr-1+ MDSCs, and
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thus reduced immunosuppression and improved the effect of a tumor vaccine in a mouse
model [27].
Gemcitabine, the nucleoside analog chemotherapeutic agent, not only exerts direct anti-
tumor activity, but also mediates tumor immunotherapeutic effects. Gemcitabine has been
shown to selectively reduce the number of CD11b+Gr-1+ cells and B cells, while preserving
CD4+ T cells and CD8+ T cells in the spleens of mice bearing murine mesotheliomas [28,29].
Gemcitabine-mediated reduction in MDSCs resulted in the amplification of CTLs, increased
activity of antitumor CD8+ T cells and NK cells, and led to the increase of immunogene-
therapy using an adenoviral-expressing IFN-β to treat large tumors [30]. Moreover, Bauer et al
showed that gemcitabine combined with DC-based vaccination increase survival in a mouse
model of pancreatic cancer, and prophylactic DC vaccination can prevent metastatisation and
orthotopic growth of murine pancreatic carcinoma cells [31].
In this report, we used A20 cells to establish a large size, murine B-cell lymphoma model.
We confirmed the accumulation of MDSCs in the spleen of lymphoma-bearing mice. Gemcita-
bine induced increased apoptosis in both cultured MDSCs and A20 cells. Injection of gemcita-
bine eliminated the majority of MDSCs in the spleen of lymphoma-bearing mice, and
produced lymphoma damage-associated molecular-pattern molecules (DAMPs) for in vivo
DC activation. Gemcitabine treatment combined with intra-tumoral injection of inactivated
DCs promoted the onsite DC maturation, induced the replication and activation of the cyto-
kine secreting NK cells and T lymphocytes, which in turn markedly reduced the size of tumor,
and extended the survival of the lymphoma-bearing mice. We demonstrated that intra-large-
size-lymphoma injection with DCs in combination with gemcitabine chemotherapy enhanced
the therapeutic efficacy of either DC-based vaccination or chemotherapeutic reagent alone.
Together with other studies, our report supports the hypothesis that gemcitabine-mediated
reduction in MDSCs significantly reduces the immune suppression in tumor-bearing animal
environment. This study established novel experimental foundation for the combination of the




Six to eight week old male BALB/c (H-2d) mice were purchased from the Center of Compara-
tive Medical Animals of Yangzhou University (Yangzhou, Jiangsu). Animal studies were per-
formed in strict accordance with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the Jiangsu Provincial Traditional Chinese Medical Hospital (Nanjing,
Jiangsu). The protocol was approved by the Committee on the Ethics of Animal Experiments
of the Jiangsu Provincial Traditional Chinese Medical Hospital (Permit Number CN-JS-2007).
Most mice died of the direct result of the lymphoma within the designated endpoint period
(120 days). Mice with certain treatment that survived beyond the endpoint period, or mice
developed tumors larger than 2800 mm3, or mice extremely suffered from the tumors and
expected to die within the same day of observation, as judged by monitoring the abnormality
of mice including lack of eating/drinking/moving activity under mild stimulation, shivering,
eye lids shut etc, were humanely euthanized on the days of observation. We monitored the
mice daily for survival studies. Mice that survived beyond the satisfied experimental designed
period (120 days) were humanely euthanized with CO2 followed by cervical dislocation. Mice
survival and death were monitored daily until their death or the experimental designed end-
point. All surgery was performed under sodium pentobarbital anesthesia, and every effort was
made to minimize suffering.
Combined Chemo- and Immuno-Therapy Inhibit Lymphoma
PLOSONE | DOI:10.1371/journal.pone.0132799 July 16, 2015 3 / 18
A20 lymphoma cell line and mouse DC cell culture
A20 B cell lymphoma cells were purchased from American Type Culture Collection (ATCC,
Manassas, VA) and maintained via ATCC protocol.
Dendritic cells preparation was performed as previously described and modified [4]. Bone
marrow–derived murine dendritic cells were generated by culturing bone marrow cells from
the femur and tibiae of BALB/c mice at a starting concentration of 1×106 cells/mL in RPMI-
1640/10% fetal bovine serum (FBS; Invitrogen, Carlsbad, California) supplemented with 30 ng/
mL of recombinant murine granulocyte macrophage colony-stimulating factor (mGM-CSF;
PeproTech, Rocky Hill, NJ) and 3 ng/mL interleukin 4 (mIL-4; PeproTech, Rocky Hill, NJ).
Fresh medium supplemented with GM-CSF plus IL-4 was added on day 3, and all of the loosely
adherent cells were transferred to Petri dishes on day 6. 2 days later, nonadherent cells and
loosely adherent dendritic cells were harvested, washed with PBS.
Immune-magnetic beads isolation of MDSCs
Mouse spleen was grinded and red blood cells were eliminated by Tris-NH4Cl. Nucleated cells
were resuspended in MACS buffer (pH7.2 PBS, 0.5% BSA, 2mM EDTA) at 1×108 cells per
0.3mL. Cells were incubated with non-specific blocking buffer and magnetic beads conjugated
Gr-1antibody at 10°C for 15 minutes. Gr-1+ cells were collected by magnetic column attraction.
Purified cells were then analyzed by flow cytometry for their immunophenotype.
Flow cytometry analysis
Lineage staining of bone marrow and spleen was performed with fluorescent conjugated anti-
bodies against Gr1, CD11b, CD11c, Ia, CD31, Ter119, CD14, F4/80, CD3, CD4, CD8, B220,
B7-1, B7-2 and DX5 (eBiosciences, San Diego, CA). Other antibodies used for flow cytometry
include: CD34, Trail, c-kit, Flk-1, Sca-1, CD40 and CD54 (BD Biosciences, Franklin Lakes, NJ).
Annexin V and PI were used for apoptosis analysis. Flow cytometry utilized Cytomics FC500
(Beckman Coulter Inc. Indianapolis IN), LSRII or FACSAria II, respectively (BD Biosciences).
Flow cytometry data was analyzed with Kaluza, Diva, or FlowJo software. Cells were first gated
with forward scatter (FSC) and side scatter (SSC) to exclude debris (small values<50 on FSC).
The gated cells were then analyzed for the specific fluorescent channels with which the stained
antibodies were conjugated. The results were represented with 2-D graphs as shown in the Fig-
ures section.
DCs were labeled as previously described [32] with carboxyfluorescein diacetate succinimi-
dyl ester (CFSE) prior to the intratumoral injection. Briefly, DCs were resuspended in PBS
(20×106/ml) and an equal volume of CFSE (5μM in PBS) was added. After 10 min at room
temperature, an equal volume of FBS was added for quenching. After one minute at 4°C, cells
were washed with HBSS. 5×106 CFSE-labeled DCs were intratumorally injected into each
mouse.
B-cell lymphomamouse model and In vivo effects of gemcitabine and
DCs
BALB/c mice were inoculated subcutaneously with 2x105 A20 lymphoma cells, palpable subcu-
taneous tumor foci were detected under the skin within fourteen days. Large tumor blocks with
a minimal volume of 700–1,000 mm3 were usually detected twenty-seven to thirty days after
inoculation. The mice were then injected intraperitoneally with a single dose of 120 mg/kg of
gemcitabine (Eli Lilly, Indianapolis, IN), or intratumorally with 5x105 cultured DCs after
48 hours, or injected with both gemcitabine and DCs. Control mice received saline only. On
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selected days after treatment, spleen cells were isolated and the single cell suspensions were
subjected to flow cytometry. Tumors volumes were estimated using the formula: (π x long axis
x short axis x short axis) / 6. Each control or experimental group had five to ten mice. Mice sur-
vival was observed, recorded and represented by Kaplan-Meier survival curves. Mice with cer-
tain treatments survived beyond the endpoint (120 days), and were euthanized with CO2
followed by cervical dislocation.
In vitro cytokine release assay
Spleen cells were harvested from the lymphoma bearing mice seven days after intra-tumoral
injection of normal saline, DCs, or co-injection of both DCs and MDSCs. 2 × 106 splenocytes
were cocultured with 2 × 105 A20 cells (25 mg/L mitomycin C treated for 30min) in 1 mL
RPMI1640 medium containing 10% FCS in 24-well tissue culture plates. After 48 hours, cell-
free supernatant were collected for measurement of murine IFNγ release by standard ELISA
according to the manufacturer’s recommendations (eBioscience), which is reported as
mean ± SD of triplicate samples.
Cytotoxicity assay
Spleens were collected from mice and 5 x 106 spleen cells were re-stimulated by co-culture with
mitomycin C (25 mg/L for 30min)-treated A20 cells (3 x 105) and 50 IU/mL murine interleukin
2 (mIL-2; PeproTech, Rocky Hill, NJ) for 5 days. After re-stimulation, target cells (2 x 104/well)
were cultured with re-stimulated splenocytes at various ratios in 96-well, round-bottomed
plates (200 μL/well) for 6 hours at 37°C. After centrifugation for 10 min at 250g, 100 μL of
supernatant from triplicate cultures were collected and the released lactate dehydrogenase
(LDH) from target cells was measured in vitro using the CytoTox 96 Non-Radioactive Cytotox-
icity Assay Kit (Promega, Madison, WI), according to the manufacturer’s protocol.
Immunofluorescent staining
For immunofluorescence staining, antibodies against DX5-PE and NKG2D-FITC were pur-
chased from eBiosciences. Tissues were fixed in 4% paraformaldehyde overnight, 30% sucrose
incubation for 48 hours, and followed by frozen sectioning (3 μm). Slides were then pre-blocked
with serum and stained with DX5 and NKG2D for one hour. Nucleuses were stained with DAPI
and the slides were visualized with laser scanning confocal microscope (Zeiss LSM710).
NK cells and T cells depletion
NK cell depletion was achieved using intraperitoneal injection of 300 mg of anti-asialo-GM1
antibody (WAKO Chemicals USA Inc, Richmond, VA) or isotype control Ab on day 24, 26,
28, 32 and day 35 (DC intratumoral injection is day 32). CD4+ and CD8+ T cells were individu-
ally depleted by intraperitoneal injection of 100 mg of anti-CD4 (GK1.5), or anti-CD8
(TIB105) mAbs (self-generated hybridomas) on day 24, 26, 28, 32 and 35 [33,34]. The effi-
ciency of NK cells and T cells depletion was validated by flow cytometry analysis of splenocytes
using anti-DX5, anti-CD4 and anti-CD8 mAbs. In all cases,>98% of the targeted cells subset
was specifically depleted (data not shown).
Data analysis
Kaplan-Meier survival curves were generated with GraphPad Prism 5 (GraphPad Software Inc,
La Jolla, CA). Flow cytometry data were analyzed with CXP Analysis (Beckman Coulter Inc.),
Diva (BD Biosciences) and FlowJo software (Tree Star Inc, Ashland, OR). Statistical analysis
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including the student t-test of the flow cytometry data, the log-rank analysis of the survival
curve was performed with Excel (Microsoft Inc, Seattle, WA), GraphPad Prism 5, and SAS 9.1
(SAS Institute Inc. Cary, NC). Statistical data with replicates were represented by the average
values and the standard deviation.
Results
Treatment of B-cell large size lymphoma in mice with either gemcitabine
or cultured DCs alone failed to prevent tumor growth
Chemotherapeutic reagent gemcitabine is routinely applied for clinical lymphoma treatment.
To examine the inhibitory effect of gemcitabine on inhibition of large lymphoma growth, we
intraperitoneally injected 120 mg/kg gemcitabine into A20 cell inoculated large lymphoma on
BALB/c mice at day 30 after inoculation. As control treatment, we injected equal volume of
normal saline into another group of tumor-bearing mice as well. Tumor developed from the
normal saline treated mice continued to grow as large as 2,500 mm3, and the mice soon died
within two weeks after saline injection (Fig 1A and 1B). For mice injected with gemcitabine, we
observed that the tumor blocks softened; their sizes slightly reduced two days after gemcitabine
treatment and maintained the same size for approximately additional ten days. This indicated
that gemcitabine restricted tumor growth by eliminating some of the tumor cells. However,
starting from the twelfth day since gemcitabine injection, tumor blocks continued to grow
beyond control and became much larger in size. The mice eventually died, about twelve days
later than those in the normal saline treatment group (Fig 1A and 1B).
Cancer vaccination with tumor cell released DAMPs-activated DCs has been shown to
induce tumor regression in cancer patients [8]. However, recent clinical trials of vaccination
with cultured, lymphoma DAMPs-activated DCs failed to demonstrate the expected, desired
results [9]. It is possible that tumor antigen activated, in vitromatured DCs may not be as effi-
cient as in vivomatured DCs in either function or quantity. To improve the potential efficacy
of the DC mediated immunotherapy, A20 cell inoculated mice were intratumorally injected
with inactivated, immature DCs. These DCs could be activated by lymphoma antigen onsite,
will migrate to and mature within lymphatic organs, and develop into lymphoma antigen
pulsed mature DCs in vivo. Intratumoral injection of DCs into lymphoma inoculated mice
demonstrated a response that was similar to the gemcitabine treatment: tumors grew slowly
and the sizes became smaller, but the tumor eventually grew out of control and the mice died
two weeks later (Fig 1A and 1B). Thus, treatment of large size lymphoma with either chemo-
therapeutic gemcitabine, or DCs therapy alone, can only modestly restrict tumor growth and
slightly extend the survival of the lymphoma-bearing mice. Neither gemcitabine nor DCs
mediated immune vaccination completely inhibited tumor cell growth or rescued these mice
died of tumor progression.
Accumulation of MDSCs in the spleen of lymphoma-bearing mice
We examined the mice thirty days after A20 cells inoculation. We found the sizes and weights of
their spleen were comparable to the control mice. But the cellular components of the spleen
were quite distinct. There were significantly increased percentages (22.3% -35.8%, n> = 10) of
Gr-1+ and CD11b+ MDSCs in the spleen of the lymphoma-bearing mice. In contrast, the per-
centages of MDSCs in the spleen of the control mice were merely 2.2% on average (Fig 2A–2C).
Because the sizes and weights of the spleen in tumor-bearing mice were slightly larger than
those of the control mice, the quantity of the Gr-1+CD11b+ MDSCs in the spleen of the tumor-
bearing mice was approximately ten times more than that in the spleen of the control mice.
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To further analyze the immunophenotype of MDSCs, spleen cells harvested from both con-
trol and tumor-bearing mice were labeled with magnetic beads or florescent dye conjugated
Gr-1 antibody and MDSCs were collected by magnetic column separation (MACS) or flores-
cence activated cell sorting (FACS). Flow cytometry analysis of the purified MDSCs confirmed
that more than 90% of cells were Gr-1+CD11b+, indicating that the sorted cells were enriched
with MDSCs (Fig 2D). These Gr-1+CD11b+ MDSCs expressed cell surface antigens c-kit, B7-1,
Flk-1 and CD14 at intermediate levels (Fig 2E).
Fig 1. Gemcitabine chemotherapy or intratumoral injection of DCs failed to completely inhibit the
growth of A20 cell induced large lymphoma onmice. A, tumor growth measurement on lymphoma-
bearing mice injected with normal saline (NS), Gemcitabine (GEM), or DCs (DC) on day 30. Tumor volume
was estimated by the formula: π x long axis x short axis x short axis) / 6. Each data point was represented by
the average value of tumors from five mice and the corresponding standard deviation. B, Kaplan Meirer
survival curve of mice injected with NS, GEM, or DC.
doi:10.1371/journal.pone.0132799.g001
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Gemcitabine induced increased apoptosis of MDSCs in vitro and in vivo
Because of the immunosuppressive effects induced by MDSCs, the significantly increased
MDSCs in the spleen may account for the poor anti-tumor effects of the A20-induced
lymphoma-bearing mice after vaccination with DCs. Thus, elimination of these MDSCs may
Fig 2. The percentage of Gr-1+CD11b+ cells in the spleens of normal mice A, andmice bearing A20
cell induced large lymphoma (30 days) B, summary with statistical analysis of average and standard
deviation were shown in C (n = 3). Flow cytometry analysis of the immunophenotype of magnetic-beads
isolated Gr1+CD11b+ MDSCs sorted from the spleens of tumor-bearing mice. D, purity check on
Gr1+CD11b+ MDSCs after sorting. E, flow cytometry analysis of the immunophenotype of isolated Gr-
1+CD11b+ MDSCs; numbers represent the percentages of positively antibody-stained cells.
doi:10.1371/journal.pone.0132799.g002
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reduce the immunosuppressive effects and potentially improve the anti-tumor immune
responses of the cancer immunotherapy. We next performed the experiment to examine
whether gemcitabine induces the increased apoptosis in MDSCs. MACS purified MDSCs were
placed in culture and incubated with normal saline or gemcitabine at 10 μg/L. After 24 to
48 hours cultured MDSCs were labeled with fluorescein conjugated Annexin-V antibody and
stained with propidium iodide (PI). In striking contrast to the control treatment, flow cytome-
try analysis showed that more than 34% and 83% of MDSCs were Annexin-V positive after 24
or 48 hours of treatment, respectively (Fig 3A and 3B). Thus, gemcitabine induces significantly
increased apoptosis in cultured MDSCs after 48 hours of treatment.
Fig 3. Gemcitabine induced apoptosis of in vitro cultured MDSCs. A,MDSCs isolated from tumor
bearing mice were incubated in culture with normal saline (NS) as controls; Gemcitabine (100 ug/ml) for 24
and 48 hours, stained with Annexin V and propidium iodide (PI), and analyzed by flow cytometry. B, results
from three replicates were summarized and represented with the average values and their standard
deviations, and statistical p-values for student t-test pair-wise comparison were included. Gemcitabine
reduced the number of MDSCs in the spleen of tumor-bearing mice. C, flow cytometry analysis of
Gr1+CD11b+ MDSCs in the spleen of non-tumor normal mice (control), mice bearing A20 cell induced large
lymphoma treated with normal saline (NS), or Gemcitabine (GEM).D, summary of the results from C with
three replicates was represented by the average values and the standard deviations, and statistical p-values
for student t-test pair-wise comparison were included.
doi:10.1371/journal.pone.0132799.g003
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We also evaluate the effect of gemcitabine on spleen MDSCs from A20-induced lymphoma-
bearing mice. Thirty days after tumor cells inoculation, mice were intraperitoneally injected
with 120mg/kg of gemcitabine, or the same volume of normal saline as control treatment.
Spleen cells were collected from these mice two days later, labeled with Gr-1 and CD11b anti-
bodies, and subject to flow cytometry analysis. As shown in Fig 3C and 3D, A20 lymphoma
cells induced to generate more than 30% of Gr1+CD11b+ MDSCs in the spleen of the tumor-
bearing mice injected with normal saline. In contrast, mice injected with gemcitabine markedly
reduced the percentage of MDSCs down to 7%, which was slightly higher than the MDSC per-
centage in non-tumor-bearing normal mice. Thus, chemotherapeutic dosage of gemcitabine
quickly eliminated the majority of spleen MDSCs both in vitro and in vivo.
Gemcitabine treated A20 cells in vivo promoted the maturation of DCs
It is conceived that intra-tumoral injected immature DCs will be activated in vivo by lym-
phoma released DAMPs and induced to differentiate within lymphatic organs, and will develop
into functional DCs. Inoculated A20 lymphoma cells from mice that were treated with normal
saline (NS) for 48 hours did induced modest DC maturation, as shown in Fig 4B (left panel;
quadrants were based on the total spleen cells from NS treated, non-tumor bearing mice). We
hypothesized that gemcitabine induced apoptosis of A20 cells in vivo generated the lymphoma
DAMPs that were even more efficient on promoting the development of DCs. To examine this,
mice inoculated with A20 cells were injected with gemcitabine and the lymphoma cells were
collected 24 hours or 48 hours later. As shown in Fig 4A, gemcitabine treatment of A20 lym-
phoma cells induced increased apoptosis in mice; the percentages of apoptotic cells further
increased 48 hours after gemcitabine injection. Bone marrow derived immature DCs were then
cultured with these lymphoma cells from NS or gemcitabine treated, A20 cell inoculated mice.
Flow cytometry analysis demonstrated that gemcitabine treated, apoptotic A20 cells markedly
increased the percentages of mature DCs with cell surface expression of CD86 (Fig 4B). To fur-
ther confirm the DCs activation in vivo, we intratumorally injected labeled bone marrow
derived immature DCs with carboxyfluorescein diacetate succinimidyl ester (CFSE) into mice
bearing lymphoma treated with or without gemcitabine. Cells from tumors, spleen and blood
Fig 4. Treatment of A20 lymphoma cells with gemcitabine increased apoptosis and promoted
dendritic cell maturation. A, flow cytometry analysis of normal saline (NS) or gemcitabine (GEM) treated
A20 cells cultured for 24 and 48 hours for annexinV and propidium iodide (PI) staining.B, flow cytometry
analysis of dendritic cell maturation induced by NS or GEM treated A20 cells (48 hours) for the expression of
CD11c and CD86.
doi:10.1371/journal.pone.0132799.g004
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were prepared for flow cytometry analysis. As shown in Fig 5, CFSE labeled DCs primarily
accumulated in lymphoma tumors rather than in other hematopoietic organs. Mice treated
with gemcitabine and injected with DCs demonstrated a significant increase (p<0.01) in the
percentage of CFSE labeled DCs in comparison to mice injected with DCs only (Fig 5A). Flow
cytometry analysis of these CFSE labeled DCs 48 hours after intratumoral injection revealed
that they were primarily mature, activated DCs with CD11c and CD86 expression (Fig 5B).
The relative increase of CFSE labeled DCs in mice treated with gemcitabine and injected with
DCs was likely due to the elimination of some lymphoma cells by gemcitabine. Compared with
NS treated lymphoma cells, gemcitabine treated A20 cells induced increased apoptosis,
Fig 5. Lymphoma bearingmice treated with gemcitabine and intratumoral injection of DCs promoted
dendritic cell maturation in vivo. CSFE labeled DCs were injected into A20 cells induced lymphoma in mice
treated with DCs alone A, or DCs and gemcitabine (GEM-DC) B, and DCs were collected from lymphoma
tissue, blood or spleen, and analyzed by flow cytometry for CSFE and DCmaturation (CD11c and CD86).
doi:10.1371/journal.pone.0132799.g005
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provided the processed, endogenous lymphoma released DAMPs, and significantly promoted
the differentiation and maturation of DCs.
Combination of gemcitabine with DCmediated tumor vaccination
significantly reduced tumor size and extended mice survival
Gemcitabine not only inhibited tumor growth by inducing apoptosis, promoted differentiation
of DCs, but also eliminated the majority of MDSCs in the spleen of the large lymphoma bear-
ing mice. We next performed the experiment to examine whether combination of gemcitabine
with immune vaccination could significantly improve the efficacy of either treatment for large
size lymphoma. Mice were first inoculated subcutaneously with A20 cells to induce B-cell lym-
phoma. Thirty days later, mice were injected with normal saline for control treatment and
developed subcutaneous tumor foci. As expected, the tumor continued to grow into large
tumor block which eventually caused the death of all animals (Fig 6A and 6B). Mice injected
with 120 mg/kg of gemcitabine were also intra-tumorally injected with cultured, activated DCs
48 hours later. Distinct from the mice injected with normal saline, mice treated with both gem-
citabine and DCs demonstrated decreased size of tumor blocks and they continued to shrink
for thirty days during observation period. The mice survived significantly longer than the con-
trol treatment group and 85% of these mice survived longer than ninety days as well. To con-
firm that the improved treatment efficacy was due to the gemcitabine caused elimination of
MSDCs, gemcitabine and DC treated lymphoma bearing mice were also injected with 5x106
purified MDSCs. The tumor of these mice grew slowly than the mice with normal saline treat-
ment. They survived longer as well. But similar to the mice treated with gemcitabine or DCs
alone, the tumor grew into larger blocks a few weeks later and the mice eventually died.
Because intra-tumorally injected DCs were efficiently activated by the gemcitabine induced
apoptosis of A20 lymphoma cells, these activated DCs would stimulate spleen lymphocytes to
produce cytokines and induce the tumor specific cytotoxic activity. To confirm this, we mea-
sured the ability of the spleen cells to produce interferon gamma (IFNγ) from A20 inoculated
lymphoma bearing mice with different treatments. As shown in Fig 6C, spleen cells from the
lymphoma bearing mice with intra-tumorally injected DCs demonstrated a fourfold increase
in producing IFNγ, when compared with the spleen cells from the normal saline or gemcita-
bine treated mice; the spleen cells from the lymphoma bearing mice that were sequentially
treated with gemcitabine and DCs showed a tenfold increase in the stimulation of IFNγ pro-
duction; co-injection of MDSCs and DCs after gemcitabine treatment reversed the increased
the production of IFNγ at a level less than the lymphoma bearing mice treated with DCs alone.
We also examined the cytotoxic activity in the lymphoma bearing mice with different treat-
ments. Similarly, spleen cells from mice that were treated with either gemcitabine or DCs
alone, demonstrated slight increase in cytotoxic activity compared with the NS treated mice.
Treatment of lymphoma bearing mice with both gemcitabine and DCs significantly increased
the cytotoxic activity of the spleen (Fig 6D). Thus, treatment of lymphoma bearing mice with
DCs alone modestly increased the ability of their spleen cells for cytokine production and cyto-
toxic activity; treatment of these mice with both gemcitabine and DCs markedly induced the
IFNγ cells and their lymphoma specific cytotoxic activity within the spleen cells.
Gemcitabine combined with DCs vaccination induced activation of NK
cells and both NK cells and T lymphocytes are required for inhibition of
tumor growth
DC induced efficient generation of CD8+ CTLs, CD4+ T helper cells and NK cells [35]. We
next sought to find out which are the primary intermediate effector cells for tumor elimination.
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Fig 6. Combination of gemcitabine chemotherapy with DC cancer vaccination efficiently inhibited the
growth of A20 cell induced large lymphoma and significantly promoted the survival of the tumor
bearingmice. A, tumor volume sizes on mice injected with normal saline (NS) on day 30, Gemcitabine on
day 30 combined with intratumoral injection of DCs on day 32 (GEM+DC), or Gemcitabine on day 30, DCs
and MDSCs on day 32 isolated from the spleen of tumor bearing mice (GEM+DC+MDSC). Each data point
was represented by the average value of the tumors from five animals and the corresponding standard
deviation. B, Kaplan Meirer survival curve of mice injected with NS, GEM+DC, or GEM+DC+MDSC. Mice
that survived beyond 120 days were euthanized. C, ELISA of the secreted IFNγ in the supernatant of cultured
spleen cells from lymphoma bearing mice re-stimulated with mytomycin C treated A20 cells for 48 hours.D,
Cytotoxic activity assays of the spleen cells from lymphoma bearing mice re-stimulated with mytomycin C
treated A20 cells and murine interleukin 2 for five days, followed by six-hour co-culture of these re-stimulated
spleen cells (effector cells) with A20 cells (target cells) at different ratios (E:T ratio); supernatant LDH
released from the target cells were measured, normalized and represented as percentages.
doi:10.1371/journal.pone.0132799.g006
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Five days after treatment of mice with normal saline, gemcitabine or/and intratumoral injec-
tion of DCs, lymphoma tissues were collected for flow cytometry and immunofluorscenece
analyses. As shown in Fig 7A, the percentage of CD4+, CD8+ cells was comparable in the
tumor samples within all four treatments. In contrast, the percentage of DX5+ cells increased
significantly in the tumor sample of mice treated with gemcitabine and injected with DCs
(p<0.01). To further confirm the increased presence of NK cells in gemcitabine treated and
DCs injected mice, we performed immunohistochemistry staining of lymphoma tissues with
both anti-DX5 (red) and anti-NKG2D (green) antibodies to label activated NK cells. Fig 7B
demonstrated the increased co-localization of both antigens (yellow), which confirmed the
increased number of NK cells in the tumor tissues of mice treated with both gemcitabine and
injected DCs. This finding indicated that it was mainly the activated NK cells accumulating in
the A20 cells induced lymphoma elimination.
Although more NK cells accumulated in the tumors than T cells when they were examined,
the kinetics of migration of T and NK cells may be different. To find out whether NK cells or T
cells are the major effector cells required for the DC initiated anti-tumor immunity, we
depleted NK cells with anti-asialo-GM1 antibody during the combination treatment of the
A20 cells induced lymphoma in mice [33]. We also depleted CD4+ and CD8+ T cells with anti-
CD4 and anti-CD8 monoclonal antibodies in parallel experiments. In contrast to the control
antibody treatment, which served as a non-specific control and demonstrated the tumor
growth curve similar to that of the combined treatment with gemcitabine and injected DCs,
co-injection of anti-asialo-GM1 antibody, gemcitabine and DCs failed to inhibit tumor growth
(Fig 7C). Injection of anti-CD4 antibody, gemcitabine and DCs did not inhibit tumor growth,
but injection of anti-CD8 antibody greatly reduced tumor sizes. CD8+ T cells depletion resulted
in delayed tumor growth compared with the tumor growth in the NK cells depletion experi-
ment (Fig 7C). Thus, gemcitabine combined with DCs vaccination induced accumulation of
NK cells in tumor; and both NK cells and CD8+ T cells appeared to be the major effector cells
mediating tumor cell elimination in vivo. In conclusion, combination of chemotherapeutic
gemcitabine and immune vaccination with DCs efficiently removed the lymphoma induced
accumulation of MDSCs, and synergistically induced the IFNr production and activation of
NK cells and CD8+ T cells, and thus enhanced anti-tumor immunity and improved the survival
of the lymphoma bearing mice.
Discussion
Lymphoma is among the cancer category that is sensitive to the DC mediated immunotherapy
[36,37,38,39]. Recently, we and others have carried out a series of basic and clinic experiments,
confirming that subcutaneous inoculation with lymphoma antigen pulsed DCs can induce
anti-lymphoma immune response. Intra-tumoral injection of non-antigen pulsed semi-mature
DCs produced even better effect on inhibition of tumor growth in a short period of time. This
is probably due to the better maintenance of the antigen processing and presenting ability of
the non-pulsed DCs, the more efficient, on-site tumor antigen acquisition and presentation
that is released from the apoptosis of the tumor cells, and the more efficient activation of the
downstream cytokine secreting Th1 and cytotoxic T-lymphocytes and NK cells. These DC
mediated immune therapies have been proposed to treat patients with relapsed or refractory
lymphoma, also due to the fact that the relapsed or refractory lymphoma tumors are often pal-
pable and it is possible for performing the accurate intra-tumoral injection of DCs.
In this work, we started with the intra-tumoral DC immunotherapy for the treatment of the
relapsed or refractory lymphoma induced by A20 cell inoculation in mice. Although we
observed that the tumor sizes reduced to half of their original sizes 4–10 days after treatment,
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Fig 7. NK cells appeared to be the major effector cells to inhibit tumor growth.Mice bearing A20 cells
induced lymphoma were treated with normal saline (NS), gemcitabine (GEM), intratumorally injected with
DCs, or the combination of gemcitabine and DC injection (GEM-DC). Tumor or spleen tissues were collected
and analyzed by A, flow cytometry NK cells (DX5) and T lymphocyte specific antigens (CD4 and CD8).B,
Immunofluorescent staining of lymphoma tissues with NK specific antibodies (DX5 red; NKG2D green), and
nucleus were stained with DAPI (blue). C, Tumor volume sizes on mice injected with normal saline (NS),
Gemcitabine combined with intratumoral injection of DCs (GEM+DC), or pre-treated with injection of anti-
asialo-GM1, anti-CD4, anti-CD8 or IgG and gemcitabine combined with intratumoral injection of DCs (GEM
+DC+anti-asialo-GM1, GEM+DC+anti-CD4, GEM+DC+anti-CD8 or GEM+DC+control-ab). Each data point
was represented by the average value of tumors from five mice and the corresponding standard deviation.
doi:10.1371/journal.pone.0132799.g007
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the tumors did not disappear; instead, they restored rapid growth 2–4 weeks later. Therefore,
intra-tumoral DC immunotherapy alone is not sufficient enough for the effective treatment of
the relapsed or refractory large lymphoma. Alternative strategies are required to improve the
current efficacy of DC based immunotherapy.
It is believed that the inefficiency of DC mediated immunotherapy was partially due to the
tumor cell induced accumulation of MDSCs in patients. MDSCs accumulated in the spleen of
tumor bearing mice and surrounding the tumor tissues to inhibit lymphocyte activation and
promote tumor angiogenesis and tumor growth. Removal of MDSCs could alleviate the tumor-
induced, MDSC-mediated immune suppression, enhance the immune response, and signifi-
cantly increase the effects of cancer vaccination in suppression of mouse tumor growth in vivo
[13]. But feasible clinic approaches to eliminate MDSCs from patients are yet to be defined and
examined. It has been reported that the all-trans retinoic acid (ATRA) and IL-4 induced
MDSCs to differentiate into mature myeloid cells and enhanced the efficacy of tumor vaccine
[27]. Our experiments demonstrated that ATRA, IL-4 or LPS failed to induce in vitro differen-
tiation of isolated Ly6C+ MDSCs, nor did they enhance the anti-tumor effects of DC vaccine
(unpublished results).
Gemcitabine has been used to treat some relapsed or refractory lymphoma. Gemcitabine not
only inhibits the growth of tumor cells by increased tumor cell apoptosis induction, it also elimi-
nates existing MDSCs from the body by inducing increased apoptosis. In our study, we demon-
strated that MDSCs accumulated in the spleen of the A20 lymphoma bearing mice. The
percentage or number of MDSCs increased up to ten times higher than the control mice. 24–48
hours incubation of 10 mg/L gemcitabine with FACS isolated MDSCs in cell culture induced
markedly increased apoptosis in MDSCs. Injection of 120mg/kg gemcitabine into A20 lym-
phoma-bearing mice eliminated the majority of Gr-1+CD11b+ MDSCs in the spleen in two
days. Gemcitabine treatment or intra-tumoral DC injection alone inhibited the tumor growth
and prolonged their survival time of the lymphoma bearing mice. But neither can completely
eliminate tumor cells or rescue the tumor bearing mice. The tumor size became much smaller a
few weeks after gemcitabine treatment. But the small number of tumor cells that were resistant
to gemcitabine eventually restored tumor growth. Intra-tumoral injection of inactivated DCs 48
hours after gemcitabine treatment could induce DCs maturation by in vivo lymphoma antigen
presentation which was generated by gemcitabine treatment. This in turn induced the cytokine
secreting cells and activated the NK and CD8+ T cells. This improved DCmediated immuno-
therapy, combined with gemcitabine chemotherapy, was believed to efficiently eliminate the
small number of residual gemcitabine resistant lymphoma cells because gemcitabine also selec-
tively removed the immune-suppressive MDSCs without causing damages on other immune
cells such as T-lymphocytes and natural killer cells. 5-fluorouracil (5-FU) is another known che-
motherapeutic agent that is capable of eliminating MDSCs in vivo. Unfortunately 5-FU has not
been approved for the treatment of lymphoma. In our study, combination of both the gemcita-
bine chemotherapy and the DCmediated immunotherapy on A20 cell induced, large lymphoma
bearing mice completely prevented the tumor growth and rescued>80% of the mice. Thus, our
study provides an improved strategy by synergizing both the chemotherapeutic agent gemcita-
bine and the intra-tumoral delivered DCmediated immunotherapy to significantly enhance the
efficacy of each individual treatment on some relapsed or refractory large lymphoma.
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